EGFR and non-small cell lung carcinoma: A previous study provided evidence that NSCLC patients with the G719X mutation of EGFR who received afatinib survived substantially longer than those with the L861G mutation, and that patients with mutation S768I had the longest survival of those with one of these three mutations.6